Incyte (INCY) 5 May 202020 Q1 Earnings call transcript

Company Profile

Participants

Michael Booth	Divisional Vice President of Investor Relations and Corporate Social Responsibility
Hervé Hoppenot	Chairman, President, and Chief Executive Officer
Barry Flannelly	Executive Vice President, General Manager, US
Steven Stein	Executive Vice President, Chief Medical Officer
Christiana Stamoulis	Executive Vice President and Chief Financial Officer
Dashyant Dhanak	Chief Scientific Officer
Marc Frahm	Cowen & Company
Cory Kasimov	JPMorgan
Salveen Richter	Goldman Sachs
Brian Abrahams	RBC
Tyler Van Buren	Piper Jaffray
Vikram Purohit	Morgan Stanley
Matt Phipps	William Blair
Tazeen Ahmad	Bank of America
Jay Olson	Oppenheimer
Michael Schmidt	Guggenheim
Mara Goldstein	Mizuho
George Farmer	BMO Capital Markets
Reni Benjamin	JMP Securities
Christopher Marai	Nomura

Call transcript

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the Incyte 2020 First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded.

I would now turn the conference over to your host, Mike Booth, Head of Investor Relations.

begin. may You

Michael Booth

incyte.com. Good who earnings Kevin. session. us today welcome Incyte’s and Barry, who section to available call Dash, on Thank by by deliver today call morning, the our and for XXXX Hervé, of Investors the conference download and used join am webcast. first Q&A joined for the Christiana, you, Steven on and I will The will are remarks, slides prepared

that many you if as ask yourself to the to as and I During question-and-answer questions question, limit needed this one session, ask allows. time will of follow-up, one enable as you

subject our remind made commercialization the for our we as I’d today compounds XXXX products, statements, call of Before the plans development pipeline, partners. results development number in to plans actual ended time in and collaboration our the including some and well regarding of our differ forward-looking our for SEC and you of other as during our like and expectations of statements documents. materially, These XXXX the the in time those the expectations statements from to that cause December to year guidance, are begin, our for risks our statements to described that a uncertainties including may XX-K are XX, forward-looking

that Accordingly, able on as important early business policies be on COVID-XX keep an governmental, today. business. this it evolving is actions to and speak pandemic assess situation, impact would statements mind that of it's to economic In and everyone I webcast as still caution is conditions social in addition, relatively to like the our our and and overall of to full

with call the Hervé. begin now We'll

Hervé Hoppenot

and hope and Mike, everyone. Thank safe and you you, morning, your families are that all healthy. I of good

the profound affected on and people's all unprecedented around and it's has every has lives time, pandemic businesses impact aspect almost this had COVID-XX world. that uncertain evident the a of During

to essential take continuing who provide a the who frontline, other all to millions want I begin, nurses moment their of services. thank people are the workers at doctors, are we Before needed to much to from

of to With want impact update relates COVID-XX our our everyone's areas on mind, this namely an earnings the and our as four at by supply, call start the it providing commercial, operations. clinical business, pandemic to forefront regulatory, I of

When health period, we to a we on-site our this proud grateful for do to and that manner deliver I'm to plans ago, a team maintain operations. that ensure to throughout here critical our customers. two receive key patients to employees and enacted global the our need our risk provide our our I'm to continue business those extremely Incyte minimizes continuity support in to to of priorities this importantly were the continuing months life-saving that at customers their and they over medicines continue working

Today, there quarter. continued we saw strong business, performance has first no been impact the and on commercial in our

We drug have are without supply and proceeding manufacturing processes our interruption. ample

and we to-date coming front, of ruxolitinib of recently XXXX, no the of and our both expect cream continue at the key not approvals for the dermatitis months. capmatinib in anticipated the regulatory NDA to year. FDA We On timelines, three tafasitamab to expect on one on announced impact key We end including submission disruption atopic other do has decision regulatory there been in timelines. the

impacted. regions by more geography patient clinical programs as anticipate on emerge are of recruitment. of we across trial clinical while our impact late-stage track, well that to continue adversely broadly global of including as remain state short-term our disease by may new of different to The disease effects as may regards With aspects development, degree today, vary and severity some programs, by as

Phase this in III pandemic, our assess cytokine In to partnership Novartis of ruxolitinib in the with address associated with global help RUX-COVID storm. patients have trial COVID-XX initiated terms effort we to recently

as for evaluating we starting trial, another potential a also treatment the COVID-XX are on patients In U.S., ruxolitinib mechanical who ventilation. are

opened allow patients to COVID-XX severe have will program, eligible an expanded ruxolitinib. receive which access with We also emergency

also role Lilly the has of agreement of ongoing which recently Diseases, where trials and clinical in with outcomes COVID-XX. are part an in evaluation its whether and the COVID-XX baricitinib plays entered global in of and Studies an as investigator-initiated arm are is with baracitinib study to ruxolitinib planned Allergy Institute into JAK-inhibition part trial. Multiple for as NIH, both a the of Infectious National ongoing baricitinib improving

of previously the execution our laid the continued $XXX million our strategy quarter commercial for plans first In the out. on benefit of Turning performance. with the results royalty over our and the $XXX the The Jakafi year, first strong total growth product to XX% by we and reach last execution long-term and to growing million first achieving year of to our XX% revenues quarter have reflect we year-over-year quarter. quarter

with $X.X in at end of also XXXX. is strong position billion financial Our QX cash the

cell the In the significant fronts. for our market, we also on of here to see and approvals the metastatic XXXX, further testament R&D provides recently FDA clinical certain with and could brings regulatory with the which treatment additional priority of refractory are and received relapsed discover cancer We with tafasitamab we capmatinib MorphoSys, with have product as Pemazyre, a development two DLBCL, we strong progress Novartis to molecule FDA. non-small recent for approval Incyte. lung of which end capabilities patients under both months, and review partners, made at the another By new inside respective collaboration

positive data remain we remain addition, of NDA to confident at end we execute to by track presented for as on ruxolitinib cream the Despite and year. COVID-XX, down uncertainties In future the on conference, at the goals. dermatitis submit about I from revolutionizing program atopic continue an III prospects the our brought Phase our our TRuE-AD we

of four Slide revenue X driving with topline over shows our the sources years ongoing growth. last revenue momentum several

Pemazyre. revenue approval We the a will fifth be adding stream of recent following

our momentum are our Jakafi to priorities maintain revenue of XXXX, to remainder to key U.S. Looking and continued drive of growth the in the

Barry Pemazyre, cover preparing approval a which We the focused launch successful and FDA will are also tafasitamab. of potential on shortly of executing for

remains LIMBER of working our pivotal priority, transformational a planned throughout for the and program and and opening XXXX key programs forward towards Incyte, Our look the the we updating expected to and of plus to year. parsaclisib BET initiation be development RUX a the shaping are you ALKX is trial. year I

who now as Jakafi our I'll more Barry will on detail for as activities quarter both over well call performance Pemazyre. the provide first pass to commercial

Barry Flannelly

patient by Slide of growth and Hervé, everyone. shows Jakafi increases strong volume. good in X you, morning, Thank mostly quarter-over-quarter, driven

higher out-of-pocket gross much to our XXXX. the net portion in for or to that in began we QX Part in was TRuE-AD responsible hole Medicare due the of increase Troop cost and expected, under D donut As are

patients The of chart The new the patients standard indications. rapidly the and In three for and total Jakafi right in with of on grow. MF, the across therapy care setting. steroid-refractory GVHD, total shows number to the GVHD PV, becoming all Jakafi of number patients treated is on continues acute

published treatment seen randomized the overall Jakafi XX% steroid-refractory the a are of GVHD. We best with in pleased XX% for REACHX REACHX a option rate response XXX-patient very Medicine, to underscoring a In acute New patients as versus importance ruxolitinib of with Journal trial, available England demonstrated have therapy.

investigators' showed to more the in of than a convincingly this options that from benefit in bailed. and show patient whom REACHX population ruxolitinib was nine was in of effective trial list therapy hard-to-treat choice steroid therapy commonly randomized first had used patients a

GVHD REACHX ruxolitinib single-arm year Results trial. this We approval are full based expected are REACHX second on also year. the ruxolitinib steroid-refractory of the applaud chronic the half last FDA study in evaluating for the granting from of in

customers outlook full for year. time, our are and strong, however, continued It remains support and for we stay to provide with to harder engage them the to and long-term a Jakafi demand result, work is Patient during awareness. Our we guidance drive that must remains positive. even focused reiterating disease as this our

We to and top ensure in strategies, success much - is and able have virtual patients had priority much are implementing our receive success their digital that implement to medicine. our in we've

Pemazyre. success U.S. take the Our commercial of methods and we Jakafi, of the learning’s apply on and launch remains focus similar to our in these

in important of cancer an oral treatment Pemazyre with is cholangiocarcinoma and the years, first innovation to portfolio represents our XX medicines. addition patients for

We team to commercial on two-thirds targeted physicians, a which effort X,XXX of allows facilitate focusing helping existing are This Pemazyre. Pemazyre of have approximately relationships, our group Jakafi. leverage behind to and are the launched already promotional of prescribing part

on through of some We virtual Jakafi. strategies will we building successfully utilizing health the care digital also promotional with professional existing are drive assets, and already programs interaction our

and in share actively teams Our affairs our the resources meetings. sales, technology with medical and materials using market customers appointments virtual scheduling virtual access in to place are and are

cholangiocarcinoma. efforts these campaign unbranded, our ongoing on complement of focused educational All

proper and patients order increasingly more with to Pemazyre, of important testing appropriate promote as to in who most from FGFR course, to continue of And treated patients enable Pemazyre. like those identifications therapies educate targeted the benefit it's are stand to

While modest, potential relatively may can that patient we be the for every commercial cholangiocarcinoma appreciate help matters. we

types are driven by pemigatinib alterations. tumor in developing other that are we So also FGFR

call over I'll Steven. that, to With turn the

Steven Stein

Starting cream, program from the X to positive share you And our few Barry. Thanks, were results weeks Phase conference with a with good ago. at morning, dermatitis revolutionizing TRuE-AD ruxolitinib atopic the everyone. we pleased very

assessment or at cream of can and see IGA-TS clinical success, As endpoint statistical week primary the ruxolitinib significance left, the on achieved you the graphs global eight. on in investigator treatment

is was significance XX% demonstrated reduction. reduction in a and reduction scale, eczema of defined severity the or four-point itch to numerical in the statistical in area NRSX, rating be which analysis EASI-XX, clinical a FDA Similarly, of index the in and and has meaningful the score terms endpoint or itch the what in

more hours rapid of we the cream initiation X.X%, see with of very concentration With reduction within importantly, a of RUX XX itch and therapy. substantial of highest

for effective motive ruxolitinib these able which together and very The of to demonstrated cream data antipyretic could anti-inflammator show a action been make has activities, strength therapy.

to relates safety or systemically that with notable findings, it safety, locally associated were were either no treatment. As there

the this vitiligo the year. XXXX. end timelines to remain ongoing continue and NDA for with ruxolitinib The We in track data are on to to expect for of at safety submit The we continue data ruxolitinib long-term trials the and been expect collected development we cream have calendar cream.

response patients rearrangements. Pemazyre. data objective response pemigatinib and now low-grade most rate FIGHT-XXX XX%, in an a adverse of with of event over where with resulted manageable. duration common median nine was fusions Pemazyre on months to Turning The in hyperphosphatemia, approved which treatment from was or study, FGFRX most based and of was of the

where the date. data to treatment is FIGHT-XXX from to options in cholangiocarcinoma, there's published we full was proud very set therapy with for are limited poor prognosis been The a recently living patients set where and offer

clinical indications. well as as pemigatinib neoplasm XpXX in We tumor-agnostic for continue to trials the myeloproliferative cancer, an study bladder

viral a mortality Now and severe immune distress infection COVID-XX by storm acute a that turning to that is causes including of is serious be efforts in which can respiratory in the leading failure patients. one COVID-XX. syndrome, a Cytokine is leads to of form overreaction respiratory triggered of complications,

G-CSF mitigate experience and massive COVID-XX Many Patients associated or of as exemplified treating storm, with believe that ultimately immune and in We by overall perpetuate inhibitor signal severe of inflammatory with and the JAKX. gamma, GM-CSF through associated filtration both damage. cytokine that storm storm cytokine reduce ruxolitinib COVID-XX pro may the elevated interferon to an IL-X, either pro-inflammatory JAKX thus disease with JAKX the burden. cytokines leading cytokine cytokines, JAKX,

to evaluate our storm. a patients associated therapy We potential as program cytokine for RUX-COVID initiated COVID-XX with recently ruxolitinib

approximately X collaboration cytokine in Our recruiting COVID-XX with our program. initiated team global Phase at We patients associated anticipate storm in Novartis a RUX-COVID. XXX partners with

be BID ICU mechanical of plus require patients who alone. ventilation endpoint milligrams standard evaluating of primary care respiratory ruxolitinib, die, acquire care care the is standard versus develop failure, X composite by XX. day of proportion or we'll And The

a COVID-XX. are to States, syndrome of trial in patients in will ARDS a characterized distressed in with evaluate second the also that We acute onset widespread XXX opening type is Phase of United the respiratory X failure, respiratory trial ruxolitinib inflammation the rapid by secondary lungs.

mechanical key difference ruxolitinib, the XX doses the and recruit those And milligrams around in expected this patients. and trial of evaluate former two ventilation, between ventilation. milligrams patients whereas are BID that RUX-COVID will is BID and on X trial XXX this trial the on is in The XXX XXX will not are trial to

is last summary. news My our flow slide

positive have As milestones, and well recent several the see, announced from including you cream data year can of premise. X approval we important FDA the already have ruxolitinib and Phase begun

the for that, call would With to financial Christiana like the I to turn update. over

Christiana Stamoulis

Thanks, this Steven. and everyone. will morning, The morning good include number. GAAP And financial update

issued deck For and backup full this GAAP, GAAP a release morning. non the slide of XX to please to reconciliation XX press to refer we of the in section and the

Before turning to our like collaboration I'd review to with treatment the quarter, results for MorphoSys. accounting the for

and has tafacitamab the two reminder, inside the tafasitamab a by of our of the co-development U.S. – and and exclusive co-commercialization by in MorphoSys with and commercialization Incyte components. The development collaboration As outside U.S. MorphoSys

how in the In accounting the be for the record terms is sales U.S. record Incyte outside collaboration, if approved, U.S. of will all will wholesales record MorphoSys will we tafacitamab will and

Our include sales the as COGS payable only U. net outside COGS the royalties will S. of on U.S. MorphoSys well as outside to

Our R&D territories a global expense specific costs, costs and XXX% as outside will of well share of include development the U.S.-specific as XX% U.S. development to any

any and prior payable are upfront include that will it to milestones addition, approval. In

outside will for expense cost only SG&A Our the U.S. tafacitamab include our commercialization

revenue or loss constitutes as item profit line it net the our a record in single an when items net financial a will it operating constitutes when a results, our we Finally, XX% of loss. as net item profit expenses as commercialization U.S. or

commercialization COGS U.S. in and tafasitamab sharing be loss this the to will with the COGS line. related in and expense included all profit costs line, the in efforts or SG&A associated not

Now and increase our of for royalty moving Jakafi in revenues, and $XXX of $XX growth an the over Lilly. from product million revenues representing XX% the This from XXXX. all million to of royalties product $XX to $XXX in be royalties across first strong Novartis first net Jakafi of exclusive is quarter continued products, quarter. comprised and total in million with results Olumiant million, in $XX million Revenue

on related expenses the include $X.X premium consisted payment stock. basis on upfront upfront a of a to Our for to of billion consideration million total of cost and $XXX which quarter the million $XXX purchase MorphoSys, $XX and the million non-GAAP MorphoSys our

R&D the for basis. R&D our on Excluding upfront milestone SG&A $XXX and ongoing was expenses million a COGS, quarter and total expenses, non-GAAP

expense a of was the on a to the representing certain $XX the XX% This the quarter timing Ongoing R&D over X% for basis, quarter. prior a basis, million increase representing year million due expense on representing primarily from year entire $XXX a expenses. non-GAAP SG&A for non-GAAP was was quarter quarter. decrease the a

loss Collaboration million, XX% the was represents for commercialization for U.S. which the tafasitamab. share a net loss quarter $X.X of

to strong in payment as offset quarter decrease MorphoSys the billion related ended the Our $X.X collaboration, with cash $X.X billion The the year-end generated during to and the financial position and upfront from continues partially cash at by we be purchase reflects securities. quarter. XXXX marketable stock flow the

R&D we our to and reiterating expense on year. for Moving are revenue, for SG&A the COGS, guidance guidance XXXX, our

presents While to communicated range was guidance $X.XX prudent first $XXX Jakafi had $X.XX million we uncertainty. exclusive performance is previously in of for $XXX the billion Jakafi billion to Therefore, of it quarter to and Iclusig. the full strong, the million retain the COVID-XX situation believe for revenue

reiterating previous we to our are billion. guidance R&D, $X.XX of For billion $X.XX

XX% portfolio, reallocation of to funds programs costs. we co-development As in a tafasitamab this now our also result cover our between expect of share

range $XXX MorphoSys. our to consideration with excludes QX guidance upfront For clarity, this the related recoded collaboration in million

will from we or commercialization Pemazyre net in collaboration, sale the the profit resulting on our for be or stage, U.S. providing early this tafasitamab at loss not of activities Finally, guidance

Please that open and concludes Operator, give prepared our your Q&A. the remarks. call instructions for

Operator

be [Operator now We’ll Instructions] Our Frahm question & question-and-answer from a first Cowen conducting is session. Marc coming Company. from Certainly.

line now is Your live.

Marc Frahm

data six, out Yes. amount getting we're LIMBER congratulations of for nine my Steven. the quarter. Maybe be It set a stage on Maybe to program Thanks of if there. a you taking question like over going and seems decent the for the the can next questions months.

in of of need kind they think therefore do see kind be own? that the be other bar When advancement half, are populations, the patient likely all all for warrant PIX-kinase data to to setting to we first and of different think kind effective in combinations on you of we evaluated or should combos the as their

Steven Stein

Marc, it's the for Steven. Thanks question. Hi,

as mean, obviously, to well. despite importance track this major So, of on focus to us I as And and Hervé upfront, the alluded remains of critical pandemic us. remains thankfully,

to combinations execution, going plus program delta. year's Phase aspects PIX-kinase then in pivotal the is And safety LIMBER, one terms plus everything is components X you there ALKX RUX In beyond as the and alluded of to, of RUX BET this monotherapy plus and moved and BET. get RUX are of the ALKX of done to three the on start else

slightly biomarker program. different. different the are behind intents have per selection se, don’t We They they're a but

So there enhance also able the ameliorate you and if look inhibition the on maintain ALKX, hepcidin to combination it's at there, both anemia enhancing through also ruxolitinib anemia the we terms of important efficacy, focus would dosing which to in and translate But being hopefully efficacy. , to safety which then hopefully expect.

dual play a that it's in So aspect.

BRD do the of some treated, maturity And potentially evolve second settings, of as sure patients thing well. data both is consolidation line terms in those idea and in possible. settings. us data particularly that watched as in of the of getting obviously, terms And combination same the but there we've ruxolitinib later there comparisons leads in and done BET In as we efficiently to much in where the needed, terms data as terms see apple-apple the first have efficacy inhibition, are enhance line in make just in to first-line we'll of that as obviously, and the if possible of

and For dosing, of terms go that being delta, very we've data the down to We've constant built carefully different done in with to we now set. experiments delta. scheduling way dosing the come

the enhanced from correctly dose, but and weaved it, in we ratio that's we're think the In of inhibition, of the terms we've Phase why not terms initiating getting from need efficacy X of toxicity delta the magnitude therapeutic the studies. the we

later up being line somewhat different lines. end versus well may The bars first in

spleen we XX% years with in screen remains set clinical remains for measured endpoints In work reduction we'll we be benefit bar something settings, line I symptom whether associated in see out response, to volume reduction. XX% regulators, with associated bar with may with and example other symptoms, the regulators. reduction a ago which speak first-line a today, a plus acceptable, we think terms as that of lower volume as later be like worked like ruxolitinib

ahead So intents three possible confident the have place in they all programs are are we're much as that then slightly a and different programs. full good to given COVID-XX, and as steam

Marc Frahm

And do on follow-up a Okay. based can I if that.

release, that combination. a Phase combination eventually dosing mentioned You BET of a the the is combination Phase started you mean inhibitor the does preparing big already press or is of X, one things says into the In you're getting beginning X it dosing? that

Hervé Hoppenot

So Marc, numerous into had We BET the ago and to of hold inhibitors a in a second clinic that put from last go over few just a sort to remind a you, ourselves we years. clinic on thrombocytopenia over then on target BET inhibitors the resurrected year little the now.

be when to that prove the will at I'm ourselves you monotherapy what on saying the XX% should to XX% Obviously, in part. absolute a be with pretty compound before hopefully and much component, what a soon about so target know toxicity the that we So, dosing as to X move range be now efficiently and relatively into dose we will much clinic that combination combination just expected the possible, less. smaller will, Phase in need We we is if were we're dose obviously as start terms then well. of versus

it go then important, semantics getting aren’t combination what about you it's because into that and efficiently here But as as possible. sufficient safety the call I think just

Marc Frahm

Thank Okay. you.

Operator

Thank you.

Kasimov is Our JPMorgan. question coming next from from Cory

now is line Your live.

Cory Kasimov

you do remdesivir especially thinking for guess, work do guys. my COVID-XX. wanted have you're And CRS? questions. Good going insight the think for RUX to protocols? in COVID-XX you in I much I your that the standard-of-care, time studies, have Hey. when your doing about you're taking you build you're to And morning, into lines first, you about ask into Thank to

of about opportunity approved And RUX can then any Thanks. the you secondly, I market ultimately this were be here? to recognize you general if primary but have potential this isn't purpose the discuss thoughts work,

Steven Stein

So Cory, your second hand over and it’s, I'll for Steven. it question. then start Herve off to

who two of cytokines, evidence And patients, are elevated yet, studies. sick in with are in XXX the RUX-COVID, with is the [indiscernible] protocol Novartis two ventilated So There's the global protocol, hospital study levels and dose again, in not. we're second not ventilated there. testing but there hopefully patients then

likely case, we so combination would would standard-of-care to treatment standard-of-care as the in arm relatively rapidly, dictated evolve be in that well this allowing knew as as on routed We day. the with and arm, evolve the ruxolitinib the in standard-of-care

and being evolved So it's looks prepared had open standard it like potential is to the for which it whatever -of-care, very now. would have much remdesivir

will to watch issue there's both that. What with of the statistical appropriate So full numbers obviously, point of related from we view, patients. to have is no that a arms

in expect standard-of-care of wouldn't and about the United are that in given no States rapidly sites Europe and we're and case, the antiviral in that us be as studies worry conducting ruxolitinib. where here would and that terms But remdesivir and with involved, to drug-drug be be a There's interaction with to Novartis adopted with the the interaction problem. particular we a

ready then we're Hervé. over do part, it opportunity So I'll market for that. to the to And hand

Hervé Hoppenot

Thank Yeah. you.

So be that mean, it relatively a we hope first, phenomenon. obviously, I short-lived would

There any CAR-T COVID-XX strong is work I very inhibition rationale. So of moved there don't a very is preclinical fast. that frankly, ruxolitinib. opportunity JAK already in of with was commercial from lot we CRS magnitude for as a We treatment. a mean, see done

is very there So good science. a

to We the frankly, this together interesting on to speed Novartis, the and work protocol go had place. was at work the put certainties, into on the see we were made a decision it to the with few minutes. Novartis where we at very [ph] to Incyte, Velcea the both phone And program which in in with able

the driven to find protocol was moved the be which that pandemic really this at for to by the situation trying speed prepared the so it the of And over solution get be world. submitted. work on could weekend We emergency around had the a team's COVID-XX the everything

the in be an part and for that up will as ruxolitinib already all then over already the We and access US program free opportunity be to think providing of receive protocol put charge. will we time of this in patients ease place --

The So are studies that's where Phase X we are. starting.

then We think in don't we I it's we as opportunity. really will work to meaningful deal situation it what Over But do we we from and from assume, side, see with are will have all FDA the market a QX trying there. I with the the our that to time, results, facing.

Cory Kasimov

All question. for Thanks taking so right. the Great. much

Operator

Thank you.

Next question from Salveen from is coming Richter Sachs. Goldman

Your live. line now is

Salveen Richter

Good morning. Thanks taking my for question.

about How The first for three the maybe to And one are You've BD as capital allocation year. four outlook? and launch in pipeline then strategy you potentially Hervé. got thinking year the context and your of this given next three well? outlook

cholangiocarcinomas then you with groundwork how And you bladder discuss Pemazyre. you. cancer? a the question in second the Thank for Can launch around up here that

Hervé Hoppenot

Yeah.

So Pemazyre. I'll Barry let speak about

continue a capital pace our BD very that revenue I XXXX. XXXX a to at to a grow what are portfolio few revenue I we window, mode think we years, fast has that in strategy, grow continue have will the much so we and demonstrated On -- line, in next to trying a diversified portfolio build have that months. six been we are over the that over the line allocation by XXXX to mean, the the in done past five,

to with potential I hematology our very it standpoint. contribute that. the a our good from to a in MorphoSys new well example product base large growth. It's dealing know think to that It's portfolio, we the is hematology. agreement revenue has It's adding and customer commercial with synergistic a the of

continue we look for type opportunity. to will that of So

field also building. the dermatology There divisions is that -- we that that now a second are we is have

that it be place So we are where opportunities could there another invest. if could where field in also good

cash a We strong now. have position

very a have strong also cash We flow.

for strategy with to our XXXX and to continue grow of to a the as new really and sort the that's these the investments. is we portfolio allocation diversify impact the in products see revenue XXXX years and these where the want to target of drive So capital a

Barry Flannelly

So part of second Salveen. your the question,

well. Pemazyre going is So launch very

a got Friday drug by we the that the proud and We Monday. on night By are on shipped we in drug we out Sunday, FDA, very center. our company of distribution had and approved

descriptions coming So in Pemazyre. are for

have paying And been market for not it. any no that with there's problem or to-date, we payers indication access

sense, better So while learned virtual the We've on a we're even it's very activities, digital it we've lots for despite now, Jakafi for doing and of in things. fact for Pemazyre. and launch, our actually doing we're a been virtual well activities, and getting going

well. going that's very So

patients the available. that, rearrangements, up cancer have or is fusions bladder the identify appropriate FGFRX have then For bladder thing important is for bladder again, most benefit physicians cancer for bladder we think data that from from testing for the moving on because, continue and FGFR thing most cholangiocarcinoma work will that to most cholangiocarcinoma we for us as alterations. in set very making that to care the testing in educate that professionals then situation And could well to they're important in sure Pemazyre are, cancer, when health to cancer, fact, we

Salveen Richter

you. Thank

Operator

Thank you.

Abrahams from RBC. Our next coming is question from Brian

Your is line now live.

Brian Abrahams

for Hi. for the I commercial my taking Thanks much guess question. Barry. on a side very question

of patterns either in duration as any quarter to of direction? COVID-XX, you're compliance longer for fills, second things and if practices seeing Jakafi wondering I'm to wondering also Just any in transplant if GVHD result scripts, on or prescription a accelerations maybe quarter as impact refills Thanks. any early like you're in exiting evolve. changes And impact see starting first

Barry Flannelly

Brian. Sure,

of your first XX particularly question for supply, XX-day Jakafi all PV only getting, haven't and patients moving changed. there supply, seen part have the more we is a of no. that's amount was that. any So for of a than into about that's least At our receive in changes days X% Generally get quarter, and actually and are of patients in MF speaking, drug any now on answer that that the for seen might prescription patients second and hasn't quarter, or is that for the first we the changes

new starts, quarter. to opposed had As a again, first very we quarter patients good first

patient to get us New normal through until starts that couple for able And should in state. of were next to be fact, a back quarters the we very good. carry more

sense. that in confident very we're So

might know, it's or areas, there those for be You GVHD, PV. high-impact whether MF some indications

of So new market fact therapy example, been you and are places patients and on GVHD for course, New in slowdown still that guidance a for our why York well-known, coming we in today. those see are Those has confident on are PV time. provided refills and the that's in start. might like long for oral MF period we for But and we of that’s City, back because patients

Brian Abrahams

That’s helpful. really Thanks.

Operator

Thanks.

question Our Piper from coming Buren Jaffray. Van is Tyler next from

now is line live. Your

Tyler Van Buren

question another Hi. on Thanks. I Good had morning. for rux COVID-XX.

Head Nages COVID-XX So, I guess, see respiratory CRS distress Palm a taskforce the and she with of cell therapy. is the was who And different is and of with recently discussing a you call here little clearly, than CRS [ph], immunomodulators respiratory distress an that had manifesting syndrome. a history ICU

mentioned every see single respiratory trial immunomodulators failed historically distress single therapy syndrome. every And in has or that have

ask relevant want is not history I guess, I So to here COVID-XX and that guys you why is why different? maybe

Steven Stein

question. Yes, it's Tyler, invoked. always good Thanks it's your have for And to learnings Steven. prior -- from studies these

apply just think, be careful here I You things. semantic other of to the labels to know, things have to catching then difference central I and that

There well. elevations reactants patients of places, on at going documented there C-reactive and China what’s have [indiscernible] like protein as evidence cytokines been the now is other you ferritin moderate If IL-X. of in that look phase of biologically on, and elevation, have information like out these and up pathophysiologically we acute going is

appropriately use that question improvement like they in you then And with then will a clinical that suppress can ruxolitinib, translate to setting. dose. we And the -- evidence is, have -- drugs

not across board entity. So just with every to it's single the patient this be for clear,

and been evidence clearly. are reactants cytokine and randomized These for to then cytokine RUXCOVID biochemical in are very or sick who is pre-ventilation, question the acute have phase storm ask hospital, of positive, patients elevation but

improvement. question result by And from it. past cytokines that's that those does you've ask. setting, to in other why the think caused COVID-XX it's the induced it's I ARDS to in this And different IL-X evolve. key then seen [indiscernible] a And have the clinical in due And may entities data

then have beyond a answered the modulate question direct there's like or these elevations the benefit cytokine studies. inhibitor JAK broad now baricitinib, like be will able to inhibition ruxolitinib mean more I randomized clinical that and a – in beyond this -- in inhibitor is or IL-X

is of to careful word some So of good, semantics. but and entity, the different is of your have we I think this caution a be

Tyler Van Buren

maybe And brief follow-up. just helpful. That's a

will to think reason there we to about is JAK’s that As comparison JAK better? IL-X be any inhibition inhibition believe in

Dashyant Dhanak

Yes. will that I This is take question. Dash.

yes, something principle, the which something all be you're in as excuse led me, to inhibition antibody, one cytokines, process JAKAFI really downstream you're with know that's through, blocking pathway. with targeting Steven -- like IL-X disease JAK the now mentioned, multiple involved signal the So, like in cytokine an you only

process. effect this, principle, in a the in And targeting going big there's I that involved event you there to out So would think by a data that downstream cytokines, know targeting have single, than should we support argue. of multiple we further protein

Tyler Van Buren

Great. taking question. Thanks for my

Operator

Thank you.

is Our from coming next question Morgan Vikram Stanley. from Purohit

Your line live. is now

Vikram Purohit

morning. Good taking Hi. Thanks for my question.

tafacitamab. had I a couple on So

so EU? the track And to I first, still see on submission in I if for MAA mid-XXXX, wanted first, the is

if to COVID-XX your you'll team see of to impact secondly, infrastructure, Europe. tafacitamab build-out I related commercializing and eventually to wanted need any disruption the be is in And having

in should initial And What expect what I frame our expecting, we Phase-I we're data expectations the for of see there? the by we for be the the believe DLBCL should to benchmark, first-line year. there? how end lastly, And can

Steven Stein

commercial Steven. will your then take. else its question, Vikram, someone the do and So third first And I'll question.

terms completely chase, to to So cut just of the it's the yeah, MAA on track. filing, in

problems to And together getting and we submit getting have had no ready appropriately. that it

Phase lymphoma, at profile safety the alone large looks diffuse Standard, R-CHOP there of B-cell plus Care of first-line without tafasitamab tafa In the the terms its And LIM addition. versus I the R-CHOP. regimen

of be a study. on That enable should and end decision two those that in which the by first data year regimens we then the is larger of potentially used III to randomized have ongoing line Phase should R-CHOP, against a

remains to safety So done, the that be component. on track

Hervé Hoppenot

maybe I coming maybe U.S., can speak about speak about And and can the Barry which sooner. is Europe

Europe, submission. in So of we stage the at are the

as And in know, you today So have a team next sort we already. place haematology, we in are year. targeting of

the obviously, expanding confinement been after take in it's will the not lead place and case. we If team expect a to We that it different us the case, we expansion be will that and direction. hope has that will lifted

the prep Barry can the and word say U.S., maybe U.S. a the Regarding for more.

Barry Flannelly

Sure.

obviously, co we're with promoting So Morphosys.

team fact, our already, so And market place sales, access and in on bringing fully actually medical team their our medical, has affairs access MorphoSys place. have and they're So in in market We actively forth. salespeople.

COVID-XX situation, tafacitamab, our and it's they're far very As large a already in current experts not goes, them if B-cell to there. diffuse as train good for actually time and in lymphoma become

as go if as a we tafacitamab fully have will professionals care that well. do of action think -- But in lot prepared of launch we for to interfere to We're goes to on, this and it we health with don't continues our even to with and continue prepare it on virtually. launch. training So

Vikram Purohit

you. Thank Okay.

Operator

William is Our from Matt coming next from Phipps Blair. question

live. Your now line is

Matt Phipps

Thanks for the my questions, two on morning. ones I-O quick programs. taking Good

Just a cancer you do a return PD-X But the your you stage investment start with prudent. not to trial, probably non-cell on three antibody? lung think that's decision think get I how

quickly compound, this follow-up And when potential a stage going to for the to we trials, kind kind pharmacodynamic safety just hit is mid then more? move Are you to you kind there of and of if later oral expansion going year, to a late indications as advance profile? see a stage of this a data

Hervé Hoppenot

oral and the the perspective take can first and of on question can antibody speak antibody portfolio I rest the the on of the about project XXX, the Maybe on on PD-X products. for Steven the Yeah. the

are in the is that a that to be is mean, typical would antibody done is is think I a being with in many the other products it portfolio I you useful rationale true used there as I that at true. remember, think have rationale bladder you combine patient that very but be a still can totally if FGFR example that beginning, PD-X population. other the potentially same The absolutely combination cancer, and are would that

we an the so-called in program the where indication that potential it, we short-term niche could the of approval of top product. have for have relatively On

of is and cancer decided that was in to the this in design two such approval cell FDA lung program X the doing other had study gain a this would cancer to then we one, without large we it the ongoing doing was line not And studies in lung ongoing. the mainly well. cancer So extraordinarily Phase non-small because problematic study And and that or lung risky. of be very is where do we first one have

the So bit an of of lung have take also overall we in indication. are with in potential cell product satisfying have the time, an that treatment would PD-X a a situation to on springboard to some that clear would in And top where have oral short-term that first-line portfolio, opportunity of strategic approved having a we have we niche of our very cancer, and for our a anti-PD-X we antibody believe us non-small where more ROI little there give program. to opportunity the a rationale is be

speak will I Steven let the So oral about program.

Steven Stein

Thanks, Hervé.

inhibition as see the range PD-LX and terms the Phase in inhibitor, active want the In terms in been recommended number well. off started what to a PD-LX of in dose we over in for of call X a year a clinic get tumor pharmacologically escalation the to microenvironment dose. we oral know we the XXX to is obviously, little the now, with That first-in-human

in we looking treating to melanoma, on naive like can where that of are the broadly the move potentially that I-O various see we But drug then that patients those in to the we those that which, entities. call areas lung, world, efficacy benchmarking. on bars, tumors, signals at And speaking, treat data settings that's the get part going and get in now from efficacy to

look and to what that of go this meat we've broadly, approaches internal in those have and proof given then the that concept, and the of your tumor the is of we've where to the able proof-of-concept seen, and therapy, those then chase again, would we bigger to if more then at we given entities, we're include look maintenance concept, settings we that types itself an internally, adjuvant then rapid exists it, Xs we various sort registration look and where well. lends have go. once to are And and want potentially year, as we where it is have proof way Once Phase decide, then at do oral which approach of question achieved it's those efficacy it settings, large

move hit very later But internally, the to work program And once the we progress trials And benchmarking in to think as enrolling speak we've we setting continues as can to we're we're and I once patients quickly. could proof-of-concept. we that as to quickly demonstrated well. comfortable we

Matt Phipps

Thank you.

Operator

America. Our coming of Ahmad from next Bank question is from Tazeen

now Your line live. is

Tazeen Ahmad

couple A of morning. Good questions.

wanted little about us on Jakafi of Going of your your idea to color get year. On sales for just back guidance, give percent an mix, maybe estimates of you a right now Medicaid? coming I from reiterating thoughts the bit to are what can

that And about has the Jakafi proportion the the I'm same. how your assumes of what this part Because for calculations into picked we streams of guidance maintaining the revenue that from that, And come higher, temporarily does year? rest that unemployment stays rate question. asking up

you reason the then And get been you. gotten sense from might Thank and you've this you're second a to question the And pipeline if for able BALVERSA? about ask, of if urothelial more thinking have also indication to hemi of any question, what a learnings I launch there's is learn that? from how in

Hervé Hoppenot

Tazeen. Sure,

covered as in Medicare we're that of far so as So situation, guess, D, this programs, Va, our other of and I patients patients, most Part Tricare government our DOD, forth. are by fact so mix fortunate in

makes XX%, patient only commercial XX% Our of is is our X% Medicaid about now. payer And about yes, population that mix up. really right

current that of and the see. Obviously, uncertainty rest But provided reinforcing go a factor we at Could the like we we're forward have it's again, with it's to for our think we up Sure. don't really with there. it to as forecasting nevertheless, our up? okay today, go guidance. we'll the guidance year XX%, big go think it's if all. And going there's But we XX%,

As BALVERSA, learned. what I from we've we learned what know don't

left Janssen future. help could educate sales us heard that at be themselves. or the FGFR haven't lot testing BALVERSA thing I they're from releasing on alterations for on heard their they a most that don't perhaps to haven't least from in And is the important Janssen, continuing seem to We

Operator

you. Thank

Oppenheimer. from Olson Jay from coming is question next Our

Your line live. now is

Jay Olson

Thanks atopic how vitiligo, COVID-XX? work What filing dermatology enrolling? about are And for are for by commercial impacted RUX what that plans is the factors study it dermatology. to And taking your build dermatitis? been Curious then in you. topical gating your Thank And Hi. has your question. the for to how infrastructure? your NDA

Steven Stein

I Again Steven. middle will your and take one. third your will Jay, and someone question first do

to to had worried the grab COVID-XX So in do in it steam monitor impact and about that we're moving remarks. remain completed on the terms on file that the ahead to remember, We said haven’t have to and we why of sites, But the we studies presented ability year. dermatitis we've the data date alluded prepared Obviously, place. and enrollment. this get remarks, we data. the slightly we atopic full that’s problems prepared of the now, And were any to by on go to submission the end in track

it's remains It's to for safety on that. why wait That of it's the plan, and steam full ahead follow-up. year, end the the the

safety the in of make of patient range year. adequate the complete by to that as the last need and we end from So get the it submission follow-up

remain on world you, minor different track our Hervé impacted important different on from a said But studies on times. track as at remind of which are to And we those I parts XXXX think to the they as vitiligo remain and In planned. COVID-XX. have enrolled terms in again, deliver there, well. studies studies, impact really really the remarks, were his of There's

Hervé Hoppenot

said On are building US, today it's plan, we of the so we true have is, the team. the commercial what and in still very process a in

have is in clinical excellent development an So team place. we already that

all the the at be high-quality group field the market of with of commercial with a what that is and a medical access, experience lot in group. commercial We looking affairs components are with of with will other

ongoing. is that is that of all So

You end heard of the The is the for this planned submission timeline. year.

date, on that. doing to track So the we being so year end you potential and launch next are can expect of the as

Outside we tell interest. looking are optionalities, and discussions had of identify a to in partner the both frankly, atopic still many do I the options alone we or stimulated the going way data are be a open, US, different have which dermatitis. can be going could on in and having excellent we of to lot it. at Europe what you best certainly would following It

at And the some looking Asia we partnership of partnerships I more for right that a need putting world, and certain of these we are would timing instead for of the for are will also and we in regions say the place other building, year. rest the

starting and plan we is commercial people. the the being of for And some market now, the shape. really it's the with build-up mean, in access marketing good I executed first already So US, as is team component said, and the with

Operator

Thank.

Schmidt is next coming Our from Michael from Guggenheim. question

line Your live. now is

Michael Schmidt

you itacitinib it Hey. might remind process. to how only and us launched such Thanks for also taking could peers [ph] compare there cancer, my going questions. bladder drugs of just back genetic profile Maybe other you think recently to but just to as not Balversa,

We've that seen wondering, going the market the in then was And launching and obviously just curious I and US terms with your itacitinib launch. of the for sales about early to the here in FDA Jakafi current overlap potential US? utilization target marketing of tafacitamab some more action back force was question And recently. second

Steven Stein

for thank and it's Steven. question first you take Michael, it. So I'll your

looking obviously, coming and in and of So the with bladder FGFRX in cancer terms there, and driver both the have intermittent at it. dosing being again, continuous data, we dosing monotherapy

impact to that COVID-XX and it. on that spoke present ago already some in data gather to We has there call of a and ability house weeks couple been our

that data So have for that in monotherapy XXXX we'll it's likely you. early more

market cash evolves drug. you We and track in, we to study evolve. of terms have patients first-line getting change profile it for in this ongoing in to treating next FGFRX we'll may early alluded inhibitor of have be and on study to in fit have that we'll evolving and does watch bladder is standard, year. obviously, terms with there and carefully, the data a Again, of see. targeted But And may we're that as combination the that Seattle a pembro. PD-X agent to have how an And first-line with

to impact seen well to program, patients those to and cancers our a them multiple and COVID-XX be different and drug. able What's multiple tumor-agnostic is management little to the us, very life given histology’s incredibly study, into We're to that's though, no important that the overall we’ve enrolling to find there. going is important get cycle the of with impact different potential there ability

And I'll then to for Barry. question, your hand it next over

Barry Flannelly

Yes, Michael.

comment between vera yes, about overlaps diffuse target about B-cell the for FDA PDUFA thing polycythemia, approvals, with population your current now anytime the our and and large and completely tafacitamab nice GVHD. and myelofibrosis, So actually, lymphoma to date and the we're launch prepared tafacitamab

Michael Schmidt

progress. Great. Thank congrats the you and on

Operator

is Goldstein from question coming Mara next Our from Mizuho.

live. now is line Your

Mara Goldstein

Great. appreciate Thanks it. the question. taking I for

when you the of be a brought Just sense you has on LIMBER of into And you the program, a point? look overall GVHD this do question of it And program. how just at at do the the then, number enhancing totality and see can the Jakafi, had treatment duration I MF on evolved patients have that of that population.

Hervé Hoppenot

to hand So, the for I for part. Steven will take it part and second it over

what for So, by of the steroid-refractory have harder get it duration duration for we really we But the is the to we months therapy, a therapy just little is MF PV trials all to believe It's clinical example. bit so, for and of by GVHD go duration acute approximately therapy GVHD of than and six go it. for for

Steven Stein

the clean program terms think MF, ability reach potential question LIMBER second the is patients more answer your for I the with and yes. And in of to

you an So, let give me example.

of get patients therapy to extra look that drug patients be on and effect patients won't benefit inhibition that, hepcidin development you then able on the ALKX, main manages one of experience it. becomes the anemia if that unmanageable We'll discontinued if is at -- ALKX So and the small of to the reasons due stay from that. number works

In the go be drug, with addition, combination. it would treated patients who on able being open to can't potentially up then

one that's example. good So

that the there's to formulation I terms look you once-daily but been being at although If potentially better there patients, our once-daily in potential a of formulation, the date, hasn't convenience work, an XR formulation, mean for that's issue upside.

up PK flatter that's [indiscernible] profile having if in ends the there. a issue may in another ultimately its has patients anemia, a use MF effect -- that terms having that induction less be increased and where the of drug because of In addition, of there

be likely or And then product have overall if just it's desired use in then lastly, BET will treating whether Delta, with you I'll the add, everything, your to more efficacy, that setting. physicians enhanced with beyond

answer on, we is to we everywhere clean pretty clear. the want yes, I So if think, get get,

Mara Goldstein

appreciate I it. you. Thank

Operator

BMO is question George Farmer coming next Our Markets. Capital from from

is line live. Your now

George Farmer

on a Good on you in any can mentioned? taking you of had indications you Hi. comment Thanks PD-X the the Hervé, that for elaborate any What on all morning. more questions. are at if commercial more and bit cancer my niche front-line Wondering, strategy. can your -- expectations lung

Hervé Hoppenot

approach So be of yes, small a the could have are we of aspects They to in for each to our of product et number of know the approach have is line first way in non-small chemotherapy the said, non-small as of are potential to In terms patients indications relatively lung important lung some many which cell with we products, combination treatment the first-line cancer, the approved patients receiving program very the niche you pipeline other mid- cancer. as in cetera. for them. cell of and the

existing successful plus productive alternative it's is So will and a will approval chemo it believe that treatment if it we number position this frankly, get indication, FDA versus it allows XXX can to revenue large will setting. give be from in us And patients chemo to the a where be an and such become that it of in that standpoint. us

an with to could over, that use can a months of as if because to the with give opportunity an it's you after oral obviously chemotherapy antibody an better our PD-X also right oral be not you PD-X single-agent injectable they while in PD-X, versus develop is It patient, oral the IV treatment imagine, to managed an are right XX setting, place chemotherapy the is product.

the there you scenario where will it cell an can where injectable the chemo oral the product. an consolidation with and with of treatment next being lung a So help receive plus patients treatment PD-X, have then of organize done months of non-small you cancer, us is

where well not of there this indication. is approval by in our we itself, is There just number of fit patients where market it lung ways with that So are could very by having number a ways in a cancer. portfolio. And gain first-line number of where a share, can small the

George Farmer

Okay. Thanks very much.

Operator

Thanks.

coming question Securities. Reni from from is Benjamin next Our JMP

me, is live. you. Your Hello, can hear not phone line now handset, your perhaps hear you mute, Reni, cannot please is your pickup we if

Reni Benjamin

XXX, Steven, particular Hey, can the good something morning. quarter. you the is congratulations collection impact Thanks data studies? and and and about taking studies Maybe on-site that's shouldn't happening? other that the it for validation that other prevent a impact in you on measures questions bit little that kind more Or of true for to -- study talk from place like disruptions if what to the could a have

the as I growth amazed think a maybe then I hitting we're keep Barry, And MF. Every a getting by time in follow-up, plateau. for like

from? PV; it in just see much GVHD how I find see are bit to Can patients. Thanks. for more you for continue growth like little about and coming a more might the these looks X,XXX MF talk you and patients MF; about You roughly. patients where that for X,XXX X,XXX potentially

Steven Stein

So start. Steven. I'll Ren, it's

across get like of a issue the for data. it a be the it time, to board, has just particularly, in of the site done So I timely terms manner. and in in, we a going to been year we're of those of from to in City in New and program. half the point get time that access And able to sites studies get there this there present lines, York XXX, on getting a obviously in to to not to was it places meet realized the ready second think ability view access just in do fit particular median median to terms In obviously, COVID try in impact

to that. that related more So issue median nothing the that's particular and than to the peculiar

Hervé Hoppenot

Barry?

Barry Flannelly

certainly we but though yes, have patients faster the X,XXX so X,XXX hangs there, total the population about in quarter-over-quarter new grow is patients – MF even PV MF or to Ren We of might patients be a Obviously, new to terms year. be XX,XXX. So continues patients, to think prevalent continues backbone, MF right. in X,XXX

duration so patients have years therapy. that's eight are of that or mostly more, that of when that for it's diagnosed been their when the all patients and I earlier, But earlier, new we're we recognizing the in because through. really comes patients many on therapy benefit earlier, newly really new starting fact, And have obviously, it's the think start physicians survival therapy, they patients starting duration getting

Reni Benjamin

for Thanks taking my questions.

Operator

Thanks.

question is Our Christopher from Nomura. today from Marai next coming

Your line is now live.

Christopher Marai

Hey, Yeah. good morning.

Just a GVHD some your comment. on follow-up of

treated, setting? I competitive the do was acute emerging acute setting on given number landscape the you and For wondering there that's how GVHD? or you Jakafi, for could just the patients And Jakafi elaborate growth whether if and going chronic the look forward at of the

Hervé Hoppenot

so is GVHD, GVHD. if it approximately is patients, are So the number X,XXX of on chronic Obviously, maybe patients that in so in far it. of there spontaneous use Jakafi

end coming some the indication get we of the -- data included it's year. think of if chronic there. this We patients that's at So those

X, population. very growth in for it's this the that of end the REACH continued Towards year patient for important

at But steroid-refractory Jakafi, in becoming standard-of-care the as acute prepared statements the GVHD. beginning fast we in the that said it's

or of of acute other drugs or would pivotal think developed would being current in in interfere necessarily compelling GVHD far has we the -- the studies, chronic in data, other steroid-refractory use GVHD. we with Some of are some Jakafi so that the – that been would data chronic GVHD that

Christopher Marai

combinations first you. start antibody potentially as combination looking relative and guess, I with you exciting Okay. to, Thank of see might be we combination pipeline? data your what about of the combination just thinking in data at when your And perhaps those to, you that some would then PD-X internal some most to current alluded

Steven Stein

Stephen. Hi. Christ, you. Thank Yeah. its

swelling tumours So track, then program, the are niche clone the as the Hervé what cholangiocarcinoma, MSI-high track is Merkel. study the three And on well. call and on sort of endometrial said, as lung we --

how if with PD-X, addition, compounds and preparing the are But like JAK here, it so use looking for future on inhibitors. will, at thanks studies for combinations to up, in multiple you bringing external the both there ongoing,

well, that FGFR is enrolling to I in the year. particular data one Those of would be importance combination. next will us as expect are internally And present now. But we the

we data the calendar year. getting you will as than likely seen So with will in be medium. it's this speak more XXXX, in we But enabling safety work over older

Christopher Marai

Okay. Thank you.

Operator

question-and-answer the the floor of reached We’ve like closing or you. Thank our Mike to I'd end to remarks. session. over turn back for further any

Michael Booth

today So thank and all you for for your your time questions.

the the have questions available for course we coming follow-up to the may to forward look talking in our IR any weeks. you team at Of investor be throughout you day will when conferences

sage a But have and for again for now, you today. in thank call And participation good day. stay the your we

Operator

teleconference. Thank you. today's That conclude does

You wonderful may participation for this We disconnect thank your And line your time. a today. have day. you at

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.